Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07777926

Evaluation of Filler Injection for Chin Profile Enhancement

The goal of this prospective study is to analyze volumetric changes in the lower face after hyaluronic acid filler injections over 90 days.

The primary aim of the study is to quantify volume change of the lower face rea over time after injection of filler. The secondary aim is to collect patient related outcomes (PROs) via FACE-Q.

Participants will receive hyaluronic acid filler injections (Restylane Lyft(for contouring of the chin. Each patient will receive FDA approved dosages of filler to the lower face region to treat chin regression or chin contouring, as per FDA approved indications.

Prior to injections patients will be imaged with 3-dimensional photogrammetry. Subjects will return post-injection in 2 weeks, 1 month, and 3 moths for re-imaging.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Chin Regression Chin Asymmetry Disease Attributes Facies Jawline Contour Deficit Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

22 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Penn Medicine

Philadelphia, Pennsylvania, 19104, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 22-55
  • Patients interested in chin profile enhancement.
  • Participants must sign the informed consent form.

Exclusion criteria

  • Prior filler for facial contouring
  • Filler injection within the past 12 months or during duration of study
  • Prior facial cosmetic surgery (i.e.. facelift)
  • Prior facial trauma (i.e.. orbital fracture)
  • Pregnant or breastfeeding at the time of injection (initial visit)
  • Planned dental work within next 2 weeks
  • The following contraindications: patients with known hypersensitivity or severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies, gram-positive bacterial protein allergies, lidocaine allergies or other local anesthetics of the amide type
  • Patients with known bleeding disorders

Treatment and study plan

HA filler

Drug

Patients will receive FDA approved dosages of filler to the lower face region to treat chin regression or contour the chin, as per FDA approved indications. Patients are limited to the maximum recommended injected dose per patient for the initial and re-treatment (touch-up) injections of 4 mL. The injected volume per injection site should not exceed 2mL, the maximum volume studied and established by the manufacturer. Prior to injections, patients will be imaged with 3-dimensional photogrammetry and take a validated survey questionnaire (FACE-Q). Subjects will return post-injection in 2 weeks, 1 month, and 3 months for re-imaging and FACE-Q survey completion.

Primary outcomes

  1. Volume change of the lower face area at 90 days post-intervention

    Time frame: 90 days

    3D-images will be collected to determine change in volume from baseline (pre-intervention) to post-intervention (90 days)

Secondary outcomes

  1. Patient Reported Outcomes

    Time frame: 90 days

    Patient-reported outcomes (PROs) will be assessed using FACE-Q questionnaires (FACE-Q), an aesthetics validated survey questionnaire, including appearance, satisfaction, psychological well-being, and treatment outcome domains. FACE-Q scores are transformed to a standardized scale ranging from 0 to 100, with higher scores generally indicating more favorable patient-reported outcomes within the measured domain.

Study contacts

Contact information is provided by the study sponsor or research team.

Aamirah McCutchen

CONTACT

[email protected]

215-360-0652

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Official study title

3-Dimensional Volumetric Analysis of a Hyaluronic Filler Injection for Chin Profile Enhancement

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Aug 20, 2026
Registry last updated
Aug 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.